Michael Gelband’s Harmony Biosciences HRMY Stock Holding History

Michael Gelband’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-64,197	Closed	-$1.8M	–	1783
2026 Q1	$1.8M	Buy	+64,197	New	+$2.11M	0.01%	820
2025 Q3	–	Sell	-116,167	Closed	-$3.67M	–	1742
2025 Q2	$3.67M	Buy	116,167 +29,643	+34%	+$954K	0.03%	513
2025 Q1	$2.87M	Buy	+86,524	New	+$3.1M	0.03%	579
2024 Q4	–	Sell	-23,686	Closed	-$947K	–	1739
2024 Q3	$947K	Buy	+23,686	New	+$832K	0.01%	986
2023 Q2	–	Sell	-59,284	Closed	-$1.94M	–	2023
2023 Q1	$1.94M	Buy	+59,284	New	+$2.7M	0.02%	888
2022 Q1	–	Sell	-8,936	Closed	-$381K	–	2385
2021 Q4	$381K	Sell	8,936 -78,780	-90%	-$3.14M	﹤0.01%	1551
2021 Q3	$3.36M	Buy	87,716 +16,732	+24%	+$539K	0.05%	530
2021 Q2	$2M	Buy	70,984 +41,248	+139%	+$1.24M	0.02%	682
2021 Q1	$982K	Sell	29,736 -78,152	-72%	-$2.74M	0.01%	919
2020 Q4	$3.9M	Buy	107,888 +88,633	+460%	+$3.58M	0.04%	319
2020 Q3	$653K	Buy	+19,255	New	+$702K	0.01%	875

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's HRMY Position: Q2 2026 in Review

Michael Gelband sold out of Harmony Biosciences (HRMY) in Q2 2026, closing a stake of 64,197 shares — an estimated $1.8M sold.

Michael Gelband first reported a position in HRMY in Q3 2020 and held it in 11 quarters. The position peaked at $3.9M in Q4 2020. 324 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

Michael Gelband reported no remaining Harmony Biosciences position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 64,197 Harmony Biosciences shares in Q2 2026, an estimated $1.8M.
Michael Gelband first reported a position in Harmony Biosciences in Q3 2020 and held it in 11 quarters.
Michael Gelband's Harmony Biosciences position peaked at $3.9M in Q4 2020.
324 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.